scholarly journals Lack of diversity in advertisements for diabetes technology

2021 ◽  
Author(s):  
Melanie C Nardi ◽  
Jessica D Archer ◽  
Richard G McGee
Keyword(s):  
Diabetes Technology

Abstract #382 The Use of Diabetes Technology in Hispanics: Addressing Challenges in Everyday Practice

2019 ◽  
Vol 25 ◽  
pp. 175
Author(s):  
Natalie Mora ◽  
Alicia Warnock
Keyword(s):  
Everyday Practice ◽  
Diabetes Technology

Diabetes technology update (CME lecture)

2019 ◽  
Author(s):  
Sze May Ng
Keyword(s):  
Diabetes Technology

A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Trans-Atlantic Comparison

2020 ◽  
Author(s):  
Ananta Addala ◽  
Marie Auzanneau ◽  
Kellee Miller ◽  
Werner Maier ◽  
Nicole Foster ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Technology Use ◽  
Hemoglobin A1c ◽  
Diabetes Technology ◽  
Design And Methods ◽  
Relationship Of ◽  
The Relationship ◽  
Pediatric Type 1 Diabetes

<b>Objective:</b> As diabetes technology use in youth increases worldwide, inequalities in access may exacerbate disparities in hemoglobin A1c (HbA1c). We hypothesized an increasing gap in diabetes technology use by socioeconomic status (SES) would be associated with increased HbA1c disparities. <p> </p> <p><b>Research Design and Methods: </b>Participants aged <18 years with diabetes duration ≥1 year in the Type 1 Diabetes Exchange (T1DX, US, n=16,457) and Diabetes Prospective Follow-up (DPV, Germany, n=39,836) registries were categorized into lowest (Q1) to highest (Q5) SES quintiles. Multiple regression analyses compared the relationship of SES quintiles with diabetes technology use and HbA1c from 2010-2012 and 2016-2018. </p> <p> </p> <p><b>Results: </b>HbA1c was higher in participants with lower SES (in 2010-2012 & 2016-2018, respectively: 8.0% & 7.8% in Q1 and 7.6% & 7.5% in Q5 for DPV; and 9.0% & 9.3% in Q1 and 7.8% & 8.0% in Q5 for T1DX). For DPV, the association between SES and HbA1c did not change between the two time periods, whereas for T1DX, disparities in HbA1c by SES increased significantly (p<0.001). After adjusting for technology use, results for DPV did not change whereas the increase in T1DX was no longer significant.</p> <p> </p> <p><b>Conclusions: </b>Although causal conclusions cannot be drawn, diabetes technology use is lowest and HbA1c is highest in those of the lowest SES quintile in the T1DX and this difference for HbA1c broadened in the last decade. Associations of SES with technology use and HbA1c were weaker in the DPV registry. </p>

scholarly journals 2020 Diabetes Technology Meeting Agenda

2021 ◽  
Vol 15 (2) ◽  
pp. 379-392
Keyword(s):  
Diabetes Technology

Diabetes Technology Use in Adults with Type 1 and Type 2 Diabetes

2020 ◽  
Vol 49 (1) ◽  
pp. 37-55 ◽  
Author(s):  
Jelena Kravarusic ◽  
Grazia Aleppo
Keyword(s):  
Type 2 Diabetes ◽  
Technology Use ◽  
Diabetes Technology

Diabetes Technology Experiences Among Latinx and Non-Latinx Youth with Type 1 Diabetes

2021 ◽  
pp. 193229682110292
Author(s):  
David Tsai ◽  
Jaquelin Flores Garcia ◽  
Jennifer L. Fogel ◽  
Choo Phei Wee ◽  
Mark W. Reid ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Young People ◽  
Technology Use ◽  
Private Insurance ◽  
Spanish Speaking ◽  
Positive Attitudes ◽  
Diabetes Technology ◽  
English Speaking ◽  
Continuous Glucose Monitors

Background: Diabetes technologies, such as insulin pumps and continuous glucose monitors (CGM), have been associated with improved glycemic control and increased quality of life for young people with type 1 diabetes (T1D); however, few young people use these devices, especially those from minority ethnic groups. Current literature predominantly focuses on white patients with private insurance and does not report experiences of diverse pediatric patients with limited resources. Methods: To explore potential differences between Latinx and non-Latinx patients, English- and Spanish-speaking young people with T1D ( n = 173, ages 11-25 years) were surveyed to assess attitudes about and barriers to diabetes technologies using the Technology Use Attitudes and Barriers to Device Use questionnaires. Results: Both English- and Spanish-speaking participants who identified as Latinx were more likely to have public insurance ( P = .0001). English-speaking Latinx participants reported higher Hemoglobin A1c values ( P = .003), less CGM use ( P = .002), and more negative attitudes about technology (generally, P = .003; and diabetes-specific, P < .001) than either non-Latinx or Spanish-speaking Latinx participants. Barriers were encountered with equivalent frequency across groups. Conclusions: Latinx English-speaking participants had less positive attitudes toward general and diabetes technology than Latinx Spanish-speaking and non-Latinx English-speaking peers, and differences in CGM use were associated with socioeconomic status. Additional work is needed to design and deliver diabetes interventions that are of interest to and supportive of patients from diverse ethnic and language backgrounds.

828-P: Inpatient Provider Experience with Diabetes Technology Use on General Medicine Wards: Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitors (CGM)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 828-P
Author(s):  
NABIL Z. MADHUN ◽  
RODOLFO J. GALINDO ◽  
JESSICA DONATO ◽  
PATRICIA HWANG ◽  
HASAN F. SHABBIR ◽  
...  
Keyword(s):  
Technology Use ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
General Medicine ◽  
Subcutaneous Insulin ◽  
Diabetes Technology ◽  
Provider Experience ◽  
Continuous Glucose Monitors

scholarly journals Thinking Like A Pancreas: A Look Ahead at Diabetes Technology in the Perioperative Setting

2007 ◽  
Vol 105 (2) ◽  
pp. 545 ◽  
Author(s):  
Marc C. Torjman ◽  
Michael E. Goldberg ◽  
Robert A. Hirsh ◽  
Jeffrey Littman
Keyword(s):  
Look Ahead ◽  
Diabetes Technology

scholarly journals Strategies to Increase Adherence through Diabetes Technology

2010 ◽  
Vol 4 (3) ◽  
pp. 661-665 ◽  
Author(s):  
Robert A. Gabbay ◽  
Kendra Durdock
Keyword(s):  
Diabetes Technology

Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology

Endocrine ◽  
2017 ◽  
Vol 56 (1) ◽  
pp. 212-216 ◽  
Author(s):  
A. Pfützner ◽  
D. Klonoff ◽  
L. Heinemann ◽  
N. Ejskjaer ◽  
J. Pickup
Keyword(s):  
Type 2 Diabetes ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
Diabetes Technology
Sign in / Sign up

Export Citation Format

Share Document